Daniel A Pollyea, Jessica K Altman, Rita Assi, Kimo Bachiashvili, Vijaya Raj Bhatt, Amir T Fathi, Kateryna Fedorov, James M Foran, Ivana Gojo, Aaron Goldberg, Aric C Hall, Brian A Jonas, Matthew R Levine, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Anand Patel, Mary-Elizabeth Percival, Alexander Perl, Kristen Pettit, Dinesh Rao, Farhad Ravandi, Zaker Schwabkey, Rory Shallis, Maximilian Stahl, Richard M Stone, Swapna Thota, Geoffrey L Uy, Alison Walker, Eunice Wang, Ajibola Awotiwon, Sydney L Roth, Katie Stehman
{"title":"NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.","authors":"Daniel A Pollyea, Jessica K Altman, Rita Assi, Kimo Bachiashvili, Vijaya Raj Bhatt, Amir T Fathi, Kateryna Fedorov, James M Foran, Ivana Gojo, Aaron Goldberg, Aric C Hall, Brian A Jonas, Matthew R Levine, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Anand Patel, Mary-Elizabeth Percival, Alexander Perl, Kristen Pettit, Dinesh Rao, Farhad Ravandi, Zaker Schwabkey, Rory Shallis, Maximilian Stahl, Richard M Stone, Swapna Thota, Geoffrey L Uy, Alison Walker, Eunice Wang, Ajibola Awotiwon, Sydney L Roth, Katie Stehman","doi":"10.6004/jnccn.2026.0028","DOIUrl":null,"url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States.1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 6","pages":"222-229"},"PeriodicalIF":16.4000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network : JNCCN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jnccn.2026.0028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States.1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
